Be Aware of Changes in the Erythropoiesis-Stimulating Agent REMS Program
June 2017
You'll hear about changes in the REMS requirements for prescribing erythropoiesis-stimulating agents (ESA) in cancer patients.
For years, hospitals have been required to verify that prescribers ordering ESAs (Procrit, Epogen, Aranesp) are certified by the REMS program...AND that cancer patients sign an informed consent.
This is due to the fact that ESAs can speed up tumor growth...and death.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote